InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.33
(
-0.07%
)
Bitcoin
61,075.16
(
-0.61%
)
Post# of 14699
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Report Keyboard Shortcuts
Prev Next

whytestocks

Send PM Follow Ignore
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

whytestocks

Re: None

Thursday, 05/02/2019 1:10:37 PM

Thursday, May 02, 2019 1:10:37 PM

Post# of 14699
News: $INVA Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol: FF/UMEC/VI) compared to Relvar/Breo Ellipt...

Find out more https://marketwirenews.com/news-releases/phase-iii-captain-study-of-trelegy-ellipta-in-patients-with-asthma-meets-primary-endpoint-8103202.html
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Report Keyboard Shortcuts
Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up